Anti-Clusterin [16B5]

Absolute Antibody

Anti-Clusterin [16B5]

7

The effect of the original format of the antibody was evaluated on lung metastasis in BALB/c mice with orthotopically implanted 4T1 cells. The antibody was able to significantly reduce lung metastasis (Lenferink et al., 2010; PMID: 19935703). A humanized version of the antibody was constructed. The humanized version of the antibody inhibited the EMT-inducing activity of clusterin on A549 NSCLC cells. Immunofluorescence was performed on A549 cells using this antibody to monitor E-cadherin expression. The combination of the humanized version of the antibody with erlotinib resulted in an enhanced anti-tumour effect (H1299 and H460 cells) (US9822170). AB-16B5 is a humanized IgG2 version of the antibody which specifically binds to tumour-associated clusterin and inhibits its activity. This antibody showed a good tumour inhibitory effect in in vivo application (Tremblay et al.; 2010). A phase I and phase II trial to assess safety and tolerability of AB-16B5 for the treatment of solid tumours was performed (Ferrario et al., 2017; NCT04364620).

ImmunoFluorescence, Neutralisation/Blocking, Other Application

IF; in vitro; in vivo; inhibition

Research Use Only

Monoclonal

16B5

CLU

clusterin

AAG4, APO-J, APOJ, CLI, CLU1, CLU2, KUB1, NA1/NA2, SGP-2, SGP2, SP-40, TRPM-2, TRPM2, clusterin, aging-associated protein 4, apolipoprotein J, complement cytolysis inhibitor, complement lysis inhibitor, complement-associated protein SP-40,40, epididymis secretory sperm binding protein, ku70-binding protein 1, sulfated glycoprotein 2, testosterone-repressed prostate message 2

Mouse

IgG1

Clusterin

Human

Human

-20°C,2°C to 8°C

12352203